Novartis plans to divest its Indian eyecare portfolio to JB Chemicals, adding to the list of MNCs reducing exposure to the Indian market. The move aligns with Novartis’ strategy to capitalize on ophthalmic therapy while offering JB Chemicals entry into a growing business segment. Global Big Pharma has been divesting branded generics to Indian companies, while Indian players are diversifying from the US generics market. The deal is expected to be announced soon. The demand for eyecare is increasing due to the ageing population and greater access, driven by the use of tablets and mobile devices.
Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News